Hematological Oncology最新文献

{"title":"Investigating the Association Between a Continuous Variable and a Time-To-Event Outcome: Going Beyond the Cut-Off Approach","authors":"Tesla Murairi Mirimo,&nbsp;Cédric Portugues,&nbsp;Laurent Remontet,&nbsp;Loic Chartier,&nbsp;Anne-Ségolene Cottereau,&nbsp;David Morland,&nbsp;Franck Morschhauser,&nbsp;Mathieu Fauvernier,&nbsp;Aurélien Belot","doi":"10.1002/hon.70105","DOIUrl":"https://doi.org/10.1002/hon.70105","url":null,"abstract":"<div>\u0000 \u0000 <p>When describing relationships between variables and an outcome, dichotomization of continuous variables remains a widely used approach in medical research despite many drawbacks: the loss of information which reduces the statistical power to detect an association, the risk of misclassification and the problem of comparability of the results. Alternative approaches based on flexible functions are available and would allow to use all the information contained in the data and thus to model the possible non-linear relation between the continuous variable and the outcome. But these alternative approaches are rarely used probably because of a lack of clear guidance. This article aimed to illustrate the use of splines through an example based on hematological study. We showed the information provided by the plot of survival probabilities at a pre-specified time and according to the level of a continuous variable, thus displaying the trends of the studied phenomenon, as compared to a simple cut-off approach. In view of the major issues surrounding the patients' health, it is more than necessary to use the most powerful statistical approaches for greater precision in the understanding of health phenomena so that we may make more informed decisions. We hope this article will encourage the use of these approaches.</p>\u0000 </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144108811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clustering Based on Innate Immunity Reveals Differential Dysregulation Based on Disease Severity in Myelodysplastic Neoplasms","authors":"Pedro Robson Costa Passos,&nbsp;Andréa Alcântara Vieira,&nbsp;Renata Pinheiro Martins de Melo,&nbsp;Ronald Feitosa Pinheiro Filho,&nbsp;Leonardo Guimarães Sampaio,&nbsp;Hermano Vinnicius Gomes dos Santos,&nbsp;Letícia Rodrigues Sampaio,&nbsp;João Victor Caetano Goes,&nbsp;Sílvia Maria Meira Magalhães,&nbsp;Ronald Feitosa Pinheiro","doi":"10.1002/hon.70104","DOIUrl":"https://doi.org/10.1002/hon.70104","url":null,"abstract":"<p>Myelodysplastic neoplasms (MDS) are clonal hematologic disorders characterized by ineffective hematopoiesis and a variable risk of progression to acute myeloid leukemia (AML). Despite growing recognition of the role of innate immunity in MDS pathogenesis, the precise mechanisms remain unclear. In this study, we analyzed bone marrow CD34+ expression data from 183 MDS patients to investigate the impact of the Toll-like receptor (TLR) pathway on disease progression. Six key innate immunity genes (<i>IRAK1</i>, <i>IRAK2</i>, <i>IRAK4</i>, <i>MYD88</i>, <i>TRAF6</i>, and <i>NFKB1</i>) were used to define two distinct immune clusters: a hyperactive immune cluster (HIC) and a moderate immune cluster (MIC). The HIC was enriched in 155 immune-related pathways and showed higher infiltration of activated natural killer cells and M1 macrophages, while the MIC exhibited increased infiltration of naïve B cells and mast cells. Differential expression analysis identified 35 genes that distinguished the clusters. Validation in an independent cohort of 82 patients revealed that reduced expression of these genes correlated with markers of advanced disease, including lower hemoglobin levels, lower neutrophil counts, altered cytogenetics, and higher bone marrow blast percentages. These findings underscore the critical role of immune dysregulation in MDS progression and highlight novel therapeutic opportunities within the innate immunity pathway for tailored interventions.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70104","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144108804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MerTK is Ectopically Expressed and Affects the Biological Function in Diffuse Large B-Cell Lymphoma","authors":"Yan Li,&nbsp;Cunzhen Shi,&nbsp;Jiazhuo Wu,&nbsp;Xiaoyan Feng,&nbsp;Wenting Song,&nbsp;Mengyuan Jin,&nbsp;Yu Chang,&nbsp;Lijuan Han,&nbsp;Ping Zhang,&nbsp;Yuqin Song,&nbsp;Jun Zhu,&nbsp;Mingzhi Zhang","doi":"10.1002/hon.70089","DOIUrl":"https://doi.org/10.1002/hon.70089","url":null,"abstract":"<div>\u0000 \u0000 <p>Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients do not receive standard rescue treatment; therefore, the exploration of new therapeutic targets for the treatment of DLBCL is urgently needed. Immunohistochemistry and western blotting were performed to determine the expression of MerTK in DLBCL. Targeted knockdown of MerTK by shRNA was conducted in DLBCL cell lines. DLBCL cell-derived xenograft models were established to evaluate the effects of MerTK in vivo. We found for the first time that MerTK, a proto-oncogene, is aberrantly highly expressed in DLBCL samples and cell lines. Targeted knockdown of MerTK or application of UNC2025, a small inhibitor of MerTK, can inhibit DLBCL cell proliferation, promote apoptosis, and inhibit G2/M phase arrest. Transcriptome sequencing was performed after targeted knockdown of MerTK, and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis revealed that the differentially expressed genes involved in the autophagy pathway, in which the expression of ANXA1 was significantly upregulated, were significantly enriched. Further studies revealed that targeted MerTK knockdown inhibited autophagy flow by increasing the expression of ANXA1 in DLBCL cells. Overexpression of ANXA1 decreased proliferation and autophagy flow in DLBCL cells. Targeted knockdown of MerTK decreased disease progression in a mouse xenograft DLBCL model in vivo. UNC2025 inhibited tumor growth in a DLBCL cell-derived xenograft model. Therefore, MerTK is ectopically expressed in DLBCL, and targeted inhibition of MerTK suppresses the growth of DLBCL in vitro and in vivo. This study provides clues for precision therapy for DLBCLs that target MerTK.</p>\u0000 </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Effectiveness of R-miniCOMP Versus R-miniCHOP in Older Non-Fit Patients With Diffuse Large B-Cell Lymphoma: Insights From a “Fondazione Italiana Linfomi” Cohort Study","authors":"Alberto Bavieri,&nbsp;Sara Veronica Usai,&nbsp;Michele Merli,&nbsp;Alice Di Rocco,&nbsp;Federica Cavallo,&nbsp;Vittorio Ruggero Zilioli,&nbsp;Manuela Zanni,&nbsp;Flenghi Leonardo,&nbsp;Dario Marino,&nbsp;Annalisa Arcari,&nbsp;Emanuele Cencini,&nbsp;Guido Gini,&nbsp;Barbara Botto,&nbsp;Alessandra Tucci,&nbsp;Clara Deambrogi,&nbsp;Plenteda Caterina,&nbsp;Bianchi Maria Paola,&nbsp;Stefan Hohaus,&nbsp;Manuel Gotti,&nbsp;Benedetta Puccini,&nbsp;Daniela Dessì,&nbsp;Coscia Marta,&nbsp;Luigi Petrucci,&nbsp;Simone Ragaini,&nbsp;Emanuela Chimienti,&nbsp;Luigi Marcheselli,&nbsp;Caterina Mammi,&nbsp;Stefano Luminari,&nbsp;Michele Spina,&nbsp;Francesco Merli","doi":"10.1002/hon.70099","DOIUrl":"https://doi.org/10.1002/hon.70099","url":null,"abstract":"<div>\u0000 \u0000 <p>The R-miniCHOP regimen is the standard first-line treatment for diffuse large B-cell lymphoma (DLBCL) in older unfit or frail patients. Recent research suggests that replacing doxorubicin with non-PEGylated liposomal doxorubicin (NPLD) is safe and effective for DLBCL. However, the outcomes of DLBCL patients receiving NPLD as part of a reduced-intensity regimen approach have yet to be investigated. This study aimed to assess non-fit DLBCL patients enrolled in the Elderly Project (EP) conducted by the Fondazione Italiana Linfomi (FIL) who were treated with R-miniCHOP or R-miniCOMP. The primary and secondary endpoints were overall survival (OS) and progression-free survival (PFS), respectively. Of the 1163 cases within the EP cohort, we identified 176 patients (18%) who resulted unfit or frail at simplified geriatric assessment (sGA) and received either R-miniCHOP (89 cases; 51%) or R-miniCOMP (87 cases; 49%). Both cohorts exhibited similar clinical characteristics, a similar distribution of unfit and frail cases using the sGA and similar Elderly Prognostic Index (EPI) scores. After a median follow-up of 28 months, the 3-year OS and PFS rates were 61% and 54% respectively, with no significant difference between R-miniCHOP and R-miniCOMP. Notably, the therapeutic regimen had no significant impact on OS (HR 1.07, 95% CI: 0.63–1.82, <i>p</i> = 0.798) or PFS (HR 1.00, 95% CI: 0.62–1.6, <i>p</i> = 0.999) even after adjusting for propensity score (PS) and inverse probability weighting (IPW). A comprehensive survival analysis within vulnerable geriatric categories (unfit and frail patients) confirmed non-significant variations in predictive efficacy between R-miniCHOP and R-miniCOMP. Of note the independent prognostic role of EPI is confirmed for both OS and PFS. This study suggests that R-miniCHOP is still the preferred treatment for unfit and frail older DLBCL. The role of R-miniCOMP for specific subgroups of older DLBCLs warrants confirmation in larger studies.</p>\u0000 </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143939287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Axicabtagene Ciloleucel Compared to Historical Treatments for Relapsed/Refractory Diffuse Large B-Cell Lymphoma of Asian Descent: A Matching Adjusted Indirect Comparison of ZUMA-1 vs REAL-TREND","authors":"Frederick L. Locke,&nbsp;Graeme Ball,&nbsp;Markqayne D. Ray,&nbsp;Tony Li,&nbsp;Eve H. Limbrick-Oldfield,&nbsp;Evan Popoff,&nbsp;Steve Kanters","doi":"10.1002/hon.70100","DOIUrl":"https://doi.org/10.1002/hon.70100","url":null,"abstract":"<p>To better understand the comparative effectiveness of axicabtagene ciloleucel (axi-cel) to historical standard of care (SoC) for the treatment of refractory diffused large B-cell lymphoma (DLBCL) among patients of Asian descent, we conducted a matching-adjusted indirect treatment comparison (MAIC) of the pivotal ZUMA-1 trial (NCT02348216) and the Asia-based REAL-TREND cohort. The individual patient data (IPD) from ZUMA-1 (<i>n</i> = 101 infused patients) used the 60-month data-cut, while the REAL-TREND cohort data consisted of aggregate data and pseudo-IPD derived from digitized curves. The outcomes were overall survival (OS), complete response (CR) and overall response rate (ORR), as reported in REAL-TREND. The MAIC weights were derived using age ≥ 60, sex, proportion of fourth line or higher (4L+) patients, international prognostic index (IPI; 0–1 vs. 2 vs. 3 vs. 4–5), and refractory to SCT. Sensitivity analyses explored the use of the intention to treat population, alternative variable alignment and use of central review assessed response. Some baseline characteristics were similar across ZUMA-1 and REAL-TREND, such as age and IPI scores, but key differences included proportion of 4L + patients (69% vs. 9%), of ECOG performance score 0–1 (100% vs. 59%), and type of refractoriness. The MAIC models aligned on prior lines and refractoriness, while differences in ECOG performance scores were captured through IPI. The resulting effective sample size for ZUMA-1 was 31.1. The estimated hazard ratio for OS was 0.27 (95% confidence interval [CI]: 0.15–0.50) and sensitivity analyses led to similar estimates. Strong effects were estimated for both ORR (odds ratio: 20.76; 95% CI: 7.18–60.02) and CR (odds ratio: 15.25; 95% CI: 6.84–33.98). The comparative efficacy of axi-cel relative to historical SoC was similar to that observed in studies restricted to Western settings. By providing outcomes data within a population of Asian-descent, we can provide better economic modeling to support reimbursements and improved access.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70100","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143930236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi-Resistant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patient Population","authors":"Massimo Breccia,&nbsp;Antonella Russo Rossi,&nbsp;Valentina Giai,&nbsp;Bruno Martino,&nbsp;Carmen Fava,&nbsp;Mario Annunziata,&nbsp;Elisabetta Abruzzese,&nbsp;Gianni Binotto,&nbsp;Claudia Baratè,&nbsp;Aurelio Pio Nardozza,&nbsp;Alessandra Misto,&nbsp;Paola Coco,&nbsp;Valeria Calafiore,&nbsp;Maria Cristina Carraro,&nbsp;Federica Cattina,&nbsp;Francesco Cavazzini,&nbsp;Maria Teresa Corsetti,&nbsp;Lara Crucitti,&nbsp;Monica Crugnola,&nbsp;Ambra Di Veroli,&nbsp;Paolo Ditonno,&nbsp;Anna Ermacora,&nbsp;Felicetto Ferrara,&nbsp;Angelo Genua,&nbsp;Antonella Gozzini,&nbsp;Stefana Impera,&nbsp;Alessandra Iurlo,&nbsp;Luciano Levato,&nbsp;Luigia Luciano,&nbsp;Maria Cristina Miggiano,&nbsp;Marco De Gobbi,&nbsp;Marco Santoro,&nbsp;Barbara Scappini,&nbsp;Anna Rita Scortechini,&nbsp;Andrea Patriarca,&nbsp;Serena Rosati,&nbsp;Sabina Russo,&nbsp;Rosaria Sancetta,&nbsp;Grazia Sanpaolo,&nbsp;Teresa Maria Santeramo,&nbsp;Silvia Sibilla,&nbsp;Federica Sorà,&nbsp;Paolo Sportoletti,&nbsp;Fabio Stagno,&nbsp;Elena Trabacchi,&nbsp;Fausto Castagnetti","doi":"10.1002/hon.70101","DOIUrl":"https://doi.org/10.1002/hon.70101","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <p>Chronic myeloid leukemia (CML) patients who have experienced failure and/or intolerance to multiple lines of treatment have limited therapeutic possibilities. Asciminib is a first-in-class tyrosine kinase inhibitor (TKI) that inhibits the ABL Myristoyl Pocket (STAMP or Specifically Targeting the ABL Myristoyl Pocket) within the <i>BCR::ABL1</i> oncoprotein. This retrospective Italian analysis reports the efficacy and safety outcomes of asciminib in treating 77 CML patients in chronic phase (CML-CP) within a compassionate use setting. Patients were heavily pretreated with a median of 3 TKIs (55.8% had prior ponatinib exposure). Overall, 57.1% and 42.9% patients switched to asciminib because of resistance and intolerance, respectively. Asciminib maintained or improved molecular responses (MRs) in most patients: as best response, 41 patients (53%) achieved a MR3 or better, with 25 patients (32.5%) reaching deep molecular response (DMR). Greater percentages of intolerant patients achieved MR compared with resistant patients, although the probability of reaching at least a MR3 was not significant between the two groups (<i>p</i> = 0.116). Patients with the T315I mutation responded to asciminib, while ponatinib pre-treated patients showed lower MR improvements compared to naïve patients and had a lower probability to reach a MR3 versus naïve patients (<i>p</i> = 0.0262). These results highlight asciminib remarkable tolerability and efficacy in real-world CML-CP patient population, including heavily pretreated patients, those intolerant and resistant to previous TKIs, and presenting several comorbidities.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trail Registration</h3>\u0000 \u0000 <p>The identification code for the MAP is CABL001AIT01M.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70101","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143930417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fixed Duration Ibrutinib-Venetoclax, a Redefinition of the CLL Treatment Landscape","authors":"Stefano Molica,&nbsp;David Allsup","doi":"10.1002/hon.70088","DOIUrl":"https://doi.org/10.1002/hon.70088","url":null,"abstract":"<div>\u0000 \u0000 <p>The fixed-duration combination of ibrutinib and venetoclax (IV) has emerged as a highly effective therapeutic strategy for treating chronic lymphocytic leukemia (CLL), marking a significant shift in the treatment paradigm for this disease. Preclinical studies have demonstrated the synergistic anti-leukemic effects of the elements of this regimen and therefore provide a strong rationale for their combined use in the clinical setting. Clinical trial data of IV has demonstrated substantial improvements in progression-free survival (PFS) rates across both treatment-naïve and relapsed/refractory CLL. Notably, a considerable proportion of patients have achieved undetectable measurable residual disease (uMRD), a key marker of deep remission. However, several critical questions remain unanswered, including the optimal duration of IV and the prognostic significance of uMRD, particularly in high-risk CLL subsets. Whilst uMRD is widely considered a surrogate for deep remission, the precise correlation of this parameter with long-term survival outcomes in IV-treated patients requires further clarification. Moreover, emergent evidence suggests that a prolonged duration of IV therapy, beyond that currently employed, may enhance MRD clearance. Future research should focus on the optimization of BTKi/venetoclax fixed-duration regimens, particularly for elderly and medically unfit patients. In this context, the development of more selective BTKis that minimize adverse events whilst maintaining effective disease control will be crucial.</p>\u0000 </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143888974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival Analysis in a Colombian Cohort of Mantle Cell Lymphoma. A Real-World Experience","authors":"Juan F. Combariza-Vallejo,&nbsp;Rocío Orduz-Rodriguez,&nbsp;Natalia Gomez-Lopera,&nbsp;Claudia C. Colmenares-Mejia,&nbsp;Fabián A. Mejía-Casadiego,&nbsp;Marcela Godoy-Corredor,&nbsp;Mario Arturo Isaza-Ruget","doi":"10.1002/hon.70085","DOIUrl":"https://doi.org/10.1002/hon.70085","url":null,"abstract":"<div>\u0000 \u0000 <p>Mantle cell lymphoma is a type of B-cell lymphoma with limited epidemiologic data in Latin America. The main objective was evaluating survival, in mantle cell lymphoma in Colombia and the influence of hematopoietic stem cell transplantation in the outcomes. In a retrospective cohort of new diagnostic Mantle Cell Lymphoma between 2010 and 2024, we identified main characteristics at diagnosis and the influence of MIPI score and ASCT. We followed patients until progression or death and compared progression-free survival and overall survival. We included 139 patients; the median age was 64 years. For patients classified as low risk according to the MIPI score, the 36-month OS rate was 79.7% (95% CI: 68%–93.5%). Intermediate risk 51.5% (95% CI: 38.2%–69.4%). And High-risk 40.4% (95% CI: 26.9%–59.5%) (<i>p</i> &lt; 0.001). In the group that underwent ASCT, the 36-month OS rate was 75.2% (95% CI: 60.1%–94.6%), and in the non-transplanted group was 49% (95% CI: 39.5%–60.7%), HR 0.38 (95% CI; 019–0.74) (<i>p</i> = 0.002). High-risk patients and those who were not transplanted had the lowest survival compared to the other categories. These findings underscore the need for risk stratification, and effective treatment strategies, including the HSCT patient population in Colombia.</p>\u0000 </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143857133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort Study","authors":"Pallawi Torka,&nbsp;Natalie S. Grover,&nbsp;Timothy J. Voorhees,&nbsp;Reem Karmali,&nbsp;Kaitlin Annunzio,&nbsp;Marcus P. Watkins,&nbsp;Andrea Anampa-Guzmán,&nbsp;Heather Reves,&nbsp;Montreh Tavakkoli,&nbsp;Beth Christian,&nbsp;Colin Thomas,&nbsp;Stefan K. Barta,&nbsp;Praveen Ramakrishnan Geethakumari,&nbsp;Nancy L. Bartlett,&nbsp;Geoffrey Shouse,&nbsp;Adam J. Olszewski,&nbsp;Narendranath Epperla","doi":"10.1002/hon.70087","DOIUrl":"https://doi.org/10.1002/hon.70087","url":null,"abstract":"<p>Given the paucity of age-specific data about biology, presentation, and treatment outcomes in adults with MZL, we sought to evaluate differences between younger (≤ 70 years) and older (&gt; 70 years) patients with MZL in a large retrospective cohort treated in the contemporary era (2010 onwards). The primary objective was progression-free survival (PFS), while secondary objectives included the evaluation of overall survival (OS) and the cumulative incidence of transformation between the 2 groups. A total of 598 patients were included in the analysis and among these 32% were &gt; 70 years of age. There were no age-based differences in the prevalence of NMZL, SMZL, and EMZL. Older patients had a higher incidence of adverse prognostic features at diagnosis such as worse performance status, advanced stage disease, and bone marrow involvement, yet were more likely to be treated with single-agent rituximab than chemoimmunotherapy. Age &gt; 70 years was associated with inferior PFS and OS after controlling for clinically relevant risk factors and accounting for differences in first-line treatment. Receipt of rituximab monotherapy was associated with significantly inferior PFS overall, however, the type of first-line therapy did not impact OS in any group. Our data suggests that despite the development of new drugs for MZL, age remains an independent predictor of inferior outcomes. Investigation of targeted therapy combinations in the first-line setting may yield the required balance of efficacy and toxicity in older adults with MZL.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70087","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143857145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline, Drug-Related and Persistent Anemia and/or Thrombocytopenia Predict Responses and Prognosis in Myelofibrosis Patients Treated With Ruxolitinib","authors":"A. Laganà,&nbsp;E. Scalzulli,&nbsp;I. Carmosino,&nbsp;M. L. Bisegna,&nbsp;S. Sorella,&nbsp;C. Ielo,&nbsp;N. Zhdanovskaya,&nbsp;M. Martelli,&nbsp;M. Breccia","doi":"10.1002/hon.70086","DOIUrl":"https://doi.org/10.1002/hon.70086","url":null,"abstract":"","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143852662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}